Phibro Animal Health Q1 2027: Brazil Upside Not Priced In
As seen on the 24/7 Wall St. homepage on November 4, 2026.
Guidance assumes zero virginiamycin sales in Brazil for the rest of fiscal 2027, so a pending regulatory approval there is free upside the $832 million market cap isn't paying for. The quarter itself cleared both lines, with Mineral Nutrition up 17% covering a $5.2 million Brazil hit.
Continue ReadingShow less
Phibro Animal Health reported adjusted diluted EPS of $0.79 for its fiscal first quarter of 2027, meeting expectations, on revenue of $386.8 million that grew 6.3% year over year. Gross margin improved to 33.2%, and a lower effective tax rate provided additional lift to the bottom line.
Two smaller segments drove the outperformance. Mineral Nutrition revenue surged 17% on stronger demand and pricing for zinc oxide, copper, and trace minerals, while Performance Products grew 16%, with margins getting an additional boost from tariff recoveries under IEEPA. Animal Health, the largest segment at $293 million in revenue, delivered sales in line with management's internal plan, though a $5.2 million decline in Brazilian virginiamycin sales on regulatory headwinds partially weighed on the segment.
Management reaffirmed its full-year outlook, targeting net sales of $1.55 billion to $1.60 billion and adjusted diluted EPS of $3.41 to $3.59, but those figures assume zero additional virginiamycin sales in Brazil for the remainder of fiscal 2027. CEO Dani Bendheim noted that the company continues to pursue regulatory approvals to make therapeutic claims for virginiamycin in Brazil, and said that with the Brazilian election now concluded, the company is optimistic about progress on those approvals.
Sponsored
That regulatory optionality sits outside a market cap of $832 million, meaning the stock is not being asked to pay for any Brazil recovery at all. If approvals materialize during the fiscal year, the revenue contribution would flow directly to the upside against guidance that has already absorbed a $5.2 million hit from the absence of those sales in Q1 alone.
Phibro also flagged that certain Animal Health costs shifted into the second quarter, a timing dynamic that helped Q1 results but sets a tougher comparison for Q2. SG&A rose 15% on higher employee-related costs, pressing operating income even as gross profit expanded. Management identified improving working capital and inventory management as a top priority for the year, noting that elevated inventory is currently weighing on cash conversion.
Mentioned: PAHC